A loss-of-function variant in GFRAL associates with increased alcohol consumption in humans

This study identifies a loss-of-function variant in the GFRAL receptor that is associated with increased alcohol consumption in humans and demonstrates that GDF15 acts as an endocrine signal induced by alcohol exposure to suppress intake, suggesting a natural mechanism for limiting alcohol consumption.

The Gist

The Big Idea: The Body's "Stop Sign" for Alcohol

Imagine your body has a sophisticated security system designed to keep you safe from poisons. Usually, when you eat something toxic, your body screams, "Stop! That hurts!" and makes you feel sick so you won't eat it again.

Scientists have long known about a hormone called GDF15 that acts like a "stop sign" for eating when your cells are stressed or poisoned. But this paper asks a new question: Does this stop sign also work for alcohol?

The short answer is yes. The study found that GDF15 is a powerful signal that tells your brain to drink less alcohol. However, if your "receiver" for this signal is broken, you might drink more without realizing why.

---

The Story in Four Parts

1. The "Hangover Hormone" (GDF15)

Think of GDF15 as a smoke alarm. When your liver gets stressed (like from drinking too much alcohol, or during pregnancy), it releases this hormone into your blood. It travels to a tiny, specialized area in your brain (the brainstem) that controls nausea and aversion.

• The Analogy: Imagine GDF15 is a text message sent from your liver to your brain saying, "Hey, we've had enough of this poison. Turn off the tap."

2. The Broken Receiver (GFRAL)

For the text message to work, your brain needs a working phone. That phone is a protein called GFRAL. It sits on the surface of brain cells and catches the GDF15 message.

• The Discovery: The researchers found a rare genetic glitch in some people. It's like having a phone with a cracked screen or a broken antenna. This specific genetic variant (a "loss-of-function" mutation) breaks the GFRAL receiver.
• The Result: People with this broken receiver don't get the "Stop!" message as clearly as others. Consequently, they tend to drink about 2.6 extra units of alcohol per week (roughly two extra pints of beer) compared to people with working receivers. They aren't necessarily "addicts" by choice; their biological brake pedal is just a little less effective.

3. The Evidence: What the Data Showed

The team looked at this from three different angles:

• The "Weekend Warrior" Test: They watched healthy people drink heavily for three days straight at Oktoberfest.
  • Result: GDF15 levels went up slightly after the binge, but not immediately. This suggests GDF15 isn't the "instant hangover" feeling; it's more of a long-term signal that says, "You've been drinking a lot lately, slow down."
• The "Heavy Drinker" Test: They measured blood in people with severe alcohol dependence.
  • Result: These people had 5 times more GDF15 in their blood than normal.
  • The Twist: Even though their bodies were screaming "STOP" with massive amounts of GDF15, they kept drinking. This suggests that in severe addiction, the brain might stop listening to the alarm, or the "receiver" (GFRAL) isn't working well enough to stop the behavior.
• The Mouse Experiment: They gave mice a shot of the GDF15 hormone.
  • Result: The mice immediately stopped drinking alcohol. They chose water over beer. This proves that if you give the "stop signal" directly, the brain listens and stops drinking.

4. Why This Matters

This study changes how we might think about treating alcohol use disorder.

• Current Thinking: We often think addiction is purely a "willpower" or "brain reward" issue.
• New Thinking: Addiction might also be a failure of the body's natural "poison detection" system.

The Analogy: Imagine trying to stop a car by pressing the brake pedal.

• In a healthy person, the brake (GDF15) works, and the car slows down.
• In a person with the genetic variant, the brake cable is frayed (broken GFRAL), so they don't slow down as much.
• In a person with severe addiction, the brake pedal is pressed all the way down, but the brakes are worn out (the brain ignores the signal).

The Takeaway

This research suggests that alcohol consumption is partly regulated by a biological "safety valve." When we drink too much, our body tries to shut us down using GDF15. If our genetic "receiver" is broken, or if our brain becomes numb to the signal over time, we keep drinking.

What's next?
The scientists hope that in the future, we might be able to create medicines that mimic this GDF15 signal. Think of it as a "super-brake" for the brain—a drug that could help people with alcohol dependence feel that natural "I've had enough" sensation, helping them quit or cut back.

Note: The study also mentions that this system might be why pregnant women often develop an aversion to alcohol (and sometimes other foods). The baby's placenta releases GDF15 to protect the developing fetus from toxins, effectively telling the mother's brain to avoid them.

Technical Summary

1. Problem Statement

Alcohol is a dose-dependent cytotoxin and teratogen, yet humans continue to consume it. While the central neurobiology of addiction is well-studied, the peripheral endocrine mechanisms that might naturally constrain alcohol intake remain unclear. Growth differentiation factor 15 (GDF15) is a stress-induced hormone known to suppress appetite via the GFRAL-RET receptor complex in the brainstem (area postrema), typically in response to toxins or cellular stress. The authors hypothesize that GDF15 may serve as a systemic feedback signal specifically induced by chronic alcohol exposure to limit further consumption, analogous to its role in pregnancy-induced aversion.

2. Methodology

The study employed a multi-modal approach combining human clinical studies, large-scale genetic analysis, in vitro molecular biology, and animal models:

• Human Clinical Studies:
  • Acute Intake: Measured GDF15 levels in 12 healthy individuals after a single intragastric bolus of ethanol (60g).
  • Sub-chronic Intake: Measured GDF15 in 3 healthy volunteers before, immediately after, and 3 weeks following a 3-day period of heavy drinking (Oktoberfest, ~22 beers/day).
  • Alcohol Dependence (AUD): Measured baseline and acute-response GDF15 in 59 treatment-seeking AUD patients.
  • Family History Study: Compared GDF15 levels in 15 AUD patients, 15 healthy offspring of AUD fathers, and 15 healthy controls, both at baseline and after an oral alcohol challenge (0.5 g/kg).
• Genetic Association Study:
  • Analyzed the UK Biobank (N = 337,122 unrelated white British individuals) for protein-truncating variants (PTVs) in GDF15, GFRAL, and RET.
  • Performed a Genome-Wide Association Study (GWAS) focusing on weekly alcohol consumption and a Phenome-Wide Association Study (PheWAS) to assess safety profiles of the identified variant.
• In Vitro Characterization:
  • Used HEK293T cells co-transfected with RET and either wild-type or the identified GFRAL variant.
  • Assessed signal transduction (AKT phosphorylation) and receptor maturation (glycosylation status of RET) via Western blotting and PNGase F deglycosylation assays.
• Animal Model:
  • Conducted a two-bottle choice preference paradigm in C57BL/6 mice (4% ethanol vs. water).
  • Administered a single subcutaneous injection of recombinant human GDF15 (1 mg/kg) to measure acute effects on voluntary alcohol and food intake.

3. Key Contributions

• Identification of a Causal Genetic Variant: Discovery of a rare frameshift variant in GFRAL (rs527905870, p.Ile339AsnfsTer36) that disrupts receptor function.
• Mechanistic Insight into Receptor Biology: Demonstration that functional GFRAL is required not only for signal transduction but also for the proper glycosylation and membrane localization of its co-receptor, RET.
• Human Phenotype Characterization: Establishment that circulating GDF15 is markedly elevated in alcohol dependence but does not respond acutely to a single dose of alcohol, suggesting a chronic stress response rather than an acute toxin response.
• Therapeutic Validation: Proof-of-concept that exogenous GDF15 can acutely suppress voluntary alcohol consumption in mice.

4. Key Results

• GDF15 Dynamics in Humans:

  • Acute vs. Chronic: A single dose of alcohol did not acutely increase GDF15 (levels slightly decreased). However, GDF15 levels tended to rise after 3 days of binge drinking.
  • Alcohol Dependence: Patients with AUD exhibited a 5-fold elevation in plasma GDF15 (mean 1,132 pg/mL) compared to healthy controls (200–300 pg/mL).
  • Genetic Risk: The GFRAL p.Ile339Asnfs variant was associated with an increase of ~2.6 UK alcohol units per week (~21g ethanol) in carriers compared to non-carriers.
  • Safety Profile: PheWAS analysis showed no associations with severe adverse phenotypes (e.g., BMI, major organ failure), though no homozygous carriers were found in the cohort.

• Molecular Mechanism (In Vitro):

  • Cells expressing the GFRAL variant failed to phosphorylate AKT in response to GDF15, confirming a loss of signaling function.
  • RET Glycosylation: Wild-type GFRAL expression resulted in the presence of the fully mature, 170 kDa glycosylated form of RET. The variant receptor led to a loss of this mature form, retaining only the immature 120 kDa form. Deglycosylation assays confirmed that the variant disrupts the maturation/stabilization of RET at the cell surface.

• Animal Studies:

  • Administration of recombinant human GDF15 to mice reduced 24-hour voluntary alcohol intake by 60%.
  • Chow intake was also reduced (38%), but the suppression of alcohol was more pronounced relative to baseline preference.

5. Significance and Implications

• Evolutionary Mechanism: The findings support a model where GDF15 acts as an endocrine "brake" on alcohol consumption, induced by the chronic cellular stress of alcohol metabolism (primarily hepatic) to protect against toxicity and teratogenicity.
• Clinical Relevance: The massive elevation of GDF15 in AUD patients suggests a compensatory mechanism that is overwhelmed by the neuroadaptations of dependence. The lack of acute induction implies that GDF15 regulates long-term intake patterns rather than immediate intoxication responses.
• Therapeutic Potential: The genetic data (loss-of-function leads to more drinking) and animal data (exogenous GDF15 leads to less drinking) suggest that the GDF15-GFRAL pathway is a viable target for treating Alcohol Use Disorder (AUD) and alcohol-related liver disease.
• Nuance in Drug Development: The study highlights a potential challenge: since AUD patients already have supraphysiological levels of endogenous GDF15, therapeutic strategies may need to overcome "pathway resistance" (diminished sensitivity in the brainstem) or utilize long-acting agonists to achieve effective central signaling.

In conclusion, this paper provides robust evidence linking the GDF15-GFRAL axis to the regulation of alcohol consumption in humans, identifying a specific genetic variant that increases risk and demonstrating the pathway's potential as a therapeutic target.